



The Effect of Thiothixene Antipsychotic Drug on Serum Lipid Peroxidation Level in Rat

Leila Safaeian^{1*} and Sayyed Ali Alavi²

¹ Isfahan University of Medical Sciences, HezarJarib Street, Isfahan, Iran

² East Sage Investigative Corporation, Isfahan Science and Technology Town, Isfahan, Iran

*Corresponding author's email: lsafaeian@yahoo.com; Tel: +98-311-7922596

ABSTRACT: Thiothixene is a first generation or typical antipsychotic drug. It has been proposed that reactive oxygen species play an important role in neurotoxic adverse effects induced by antipsychotics. In this study, the serum lipid peroxidation level as a marker of oxidative stress was evaluated in rats' serum. Adult male Wistar rats received chronic administration of thiothixene by daily intraperitoneal injections (10 and 30 mg/kg) for 14 days. Normal control animals received vehicle. Carbon tetrachloride (CCl₄) was administered in rats as positive control. Malondialdehyde as an end product of lipid peroxidation was measured in serum samples by spectrophotometric assay. CCl₄ increased Malondialdehyde levels ($P < 0.05$) but serum lipid peroxidation levels were not altered by any doses of thiothixene. There was also normal body weight gain after treatment with thiothixene unlike significant reduction in body weight in CCl₄-treated animals ($P < 0.05$). The results of present study revealed no undesirable effect on serum lipid peroxidation level and body weight gain after thiothixene treatment however more researches on various tissues especially brain tissue with different doses and durations and also evaluation of different markers of oxidative stress are required for better understanding the mechanism of thiothixene adverse effects.

KEYWORDS: Thiothixene, lipid peroxidation, rat

INTRODUCTION

Schizophrenia is a severe and complex mental disorder and affects 24 million people worldwide according to the last report of World Health Organization (WHO) in 2011. This chronic disease is one of the most disabling disorders which requires long-term antipsychotic treatment (WHO, 2011). Typical and atypical antipsychotic medications are the most effective treatment for schizophrenia (Stargardt et al., 2008). First generation of antipsychotics, known as typical antipsychotic drugs are yet the most frequently used treatment for schizophrenia based on their lower cost (Tyrer and Kendall, 2009). Effective typical antipsychotic agents include phenothiazines, thioxanthenes, butyrophenones and diphenylbutylpiperidines. Thioxanthene derivatives which is exemplified primarily by thiothixene, are chemically related to phenothiazines with a tricyclic structure. They have carbon atom in place of the nitrogen atom in the central ring of phenothiazines with the side-chain substituent linked through a double bond (Pedersen, 1996).

Antipsychotic medications are usually helpful in treating symptoms and behaviors associated with the disorder, but they can cause various side effects. Extrapyramidal adverse effects included acute dystonic reactions, neuroleptic-induced parkinsonism and akathisia are common with typical antipsychotics such as

haloperidol, fluphenazine, thiothixene, and trifluoperazine. Long-term use of these antipsychotic medications may also increase risk for movement disorders such as tardive dyskinesia or dystonia (Malhotra et al., 1993). The blockade of nigrostriatal dopamine tracts and supersensitivity response to chronic dopamine blockade are implicated in these side effects (Glazer, 2000). However, new hypothesis suggest that increase in striatal glutamatergic neurotransmission and neuronal damage by oxidative stress induced by antipsychotics may be involved in extrapyramidal effects, tardive dyskinesia and also in other adverse effects (Tsai et al., 1998). The increased levels of lipid peroxidation products and decreased vitamin E levels have been reported in dyskinetic patients (Brown et al., 1998). Production of reactive oxygen species, decrease in antioxidant defense enzymes and oxidative damage has been reported in rat brain by some first generation antipsychotics such as haloperidol (Martins et al., 2008; Pillai et al., 2007). Long-term treatment with some phenothiazines such as fluphenazine has been also associated with increase in lipid peroxidation levels in liver and kidney homogenates of rats (Corte et al., 2009). Although there are many studies on phenothiazine and butyrophenone derivatives of typical antipsychotics but since there is no any report

about the effect of thiothixene on oxidative status, we evaluated lipid peroxidation level after treatment with thiothixene in animal model for better understanding the mechanism of side effects of thioxanthene derivatives and preventing them in the treatment of psychosis.

MATERIALS AND METHODS

Adult male Wistar rats (150-200 g body weight), obtained from Pasteur Institute (Tehran, Iran) were used. Animals were housed in standard laboratory cages at room temperature and ambient humidity and had access to water and rodent laboratory chow *ad libitum*. The rats were acclimated to the laboratory conditions for at least 1 week prior to the experiments. All experiments were carried out in accordance with international guideline of the care and use of laboratory animals. Thiothixene and all reagents for biochemical assay were purchased from Merck (Germany).

Animals were divided into four experimental groups with six rats each. Groups 1 and 2 received chronic administration of thiothixene by daily intraperitoneal injections (i.p., 10 and 30 mg/kg, respectively) for 14 days (Florey, 1989). Normal or negative control animals in group 3 received vehicle. Carbon tetrachloride (CCl₄) was administered i.p. at dose of 0.8 mg/kg, 30% in olive oil solution in group 4, twice a week for 2 weeks as positive control group (Morakinyo et al., 2012). Rats were weighed and killed by decapitation at the end of the second week; blood was collected and allowed to clot for preparation of serum. Thiobarbituric acid reactive substances (TBARS) were measured in serum samples as indicator of lipid peroxidation level according to the method described by Thayer WS. In brief, serum was mixed with 20% trichloroacetic acid and the precipitate was dispersed in H₂SO₄ and mixed with freshly prepared 0.67% 2-thiobarbituric acid (TBA) solution in Na₂SO₄. After extraction with n-butanol, the absorbance of the chromogen formed between the end product of lipid peroxidation and TBA was measured at 532 nm and expressed as malondialdehyde (MDA) equivalents in nmol/ml (Thayer, 1984).

Data were presented as mean \pm S.E.M (standard error of mean) and statistical analysis was made by one-way ANOVA followed by Dunnett analysis. *P* value <0.05 was considered statistically significant.

RESULTS

CCl₄ as an inducer of oxidative stress increased MDA levels (*P*<0.05). However, the results from determination of serum lipid peroxidation level in other groups showed that MDA levels were not altered by any doses of thiothixene in comparison with vehicle treated animals (Figure 1). The results of body weight measurement also showed significant reduction in body

weight in CCl₄-treated animals (*P*<0.05) while there was normal body weight gain in other groups (Table 1).




Figure 1. The effect of thiothixene on serum lipid peroxidation level. Thiothixene (10 and 30 mg/kg, i.p.) was administered in rats for 14 days. Normal control animals received vehicle. CCl₄ was administered as positive control. Lipid peroxidation was determined by measuring thiobarbituric acid reactive substances (TBARS) and expressed as MDA equivalents in nmol/ml. Data are presented as mean \pm SEM of n = 6. * = *P* < 0.05 versus normal control.

Table 1. Effect of thiothixene and CCl₄ on body weight in rats

Treatment	Initial body weight (g)	Final body weight (g)	Weight gained (g)
Normal Control	170.5 \pm 5.2	185.5 \pm 4.1	15
CCl ₄	172.2 \pm 3.5	174.7 \pm 3.7	2.5*
Thiothixene 10	167.3 \pm 4.7	183.5 \pm 5.3	16.2
Thiothixene 30	173 \pm 3.8	187.5 \pm 5.1	14.5

Weight values are mean \pm S.E.M of six rats per group. *Significant difference (*p*<0.05) with control value.

DISCUSSION

Oxidative stress has been implicated in the pathogenesis of schizophrenia and also antipsychotics toxicity (Martins et al., 2008; Corte et al., 2009; Do et al., 2009). Although short-term antipsychotic treatment has been associated with reduced oxidative stress in schizophrenia but long-term administration has been shown to induce oxidative stress (Brown et al., 1998; Pillai et al., 2007; Chittiprol et al., 2010). It has been proposed that oxidative stress may be involved in various side effects caused by antipsychotics such as extrapyramidal adverse effects and metabolic derangements (Roberts and Sindhu, 2009).

Our findings showed no difference in serum oxidative status after treatment with thiothixene in normal animal model. The results of researches suggest dual

activity for antipsychotic medications. While some phenothiazines are able to act as an antioxidant by scavenging of free radicals and inhibiting of lipid peroxidation, they are also able to release free radicals during the several oxidation processes following the metabolism in the human body or photoionization (Jeding et al., 1995; Souza dos Santos et al., 2007; Dhaunsi et al., 1993). It is possible that dosage and treatment duration, adaptive response or the result of compensatory biological processes may be involved in this paradox activity of neuroleptic drugs (Venkatasubramanian, 2012). These responses may also be tissue dependent since some antipsychotic-induced oxidative stress has been reported only in rat brain (Martins et al., 2008).

Our results also showed normal body weight gain after thiothixene treatment. The mechanisms of significantly reduced the gain in body weight from CCl₄ toxicity have not been clearly established. However there are some reports that dopamine antagonism with thioxanthenes can inhibit anorectic behavior, improved body weight gain and increased food intake (Verhagen et al., 2009).

In conclusion, the results of the present study revealed no undesirable effect on serum lipid peroxidation level and body weight gain after thiothixene treatment normal serum lipid peroxidation level and normal body weight gain may be resulted after thiothixene treatment however for better understanding the mechanism of thiothixene side effects, more researches on various tissues especially brain tissue with different doses and durations and also evaluation of different markers of oxidative stress are needed.

REFERENCES

- Brown K, Reid A, White T, Henderson T, Hukin S, Johnstone C and Glen A (1998). Vitamin E, lipids, and lipidperoxidation products in tardive dyskinesia. *Biological Psychiatry* 43: 863–867.
- Chittiprol S, Venkatasubramanian G, Neelakantachar N, Babu SV, Reddy NA, Shetty KT and Gangadhar BN (2010). Oxidative stress and neopterin abnormalities in schizophrenia: A longitudinal study. *Journal of Psychiatric Research* 44: 310–313.
- Corte CL, Fachinnetto R, Puntel R, Wagner C, Nogueira CW, Soares FA and Rocha JB (2009). Chronic treatment with fluphenazine alters parameters of oxidative stress in liver and kidney of rats. *Basic and Clinical and Pharmacological Toxicology* 105: 51-57.
- Dhaunsi GS, Singh B, Singh AK, Kirschner DA and Singh I (1993). Thioridazine induces lipid peroxidation in myelin of rat brain. *Neuropharmacology* 32: 157-167.
- Do KQ, Cabungcal JH, Frank A, Steullet P and Cuenod M (2009). Redox dysregulation, neurodevelopment, and schizophrenia. *Current Opinion in Neurobiology* 19: 220–230.
- Florey K (1989). *Analytical Profiles of Drug Substances*, Volume 18. Academic Press Inc, San Diego California, pp. 555.
- Glazer WM (2000). Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. *Journal of Clinical Psychiatry* 61: 16 s -21s.
- Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, Jenner P and Halliwell B (1995). Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. *Biochemical Pharmacology* 49: 359-365.
- Malhotra AK, Litman RE and Pickar D (1993). Adverse effects of antipsychotic drugs. *Drug Safety* 9: 429-436.
- Martins MR, Petronilho FC, Gomes KM, Dal-Pizzol F, Streck EL and Quevedo J (2008). Antipsychotic-induced oxidative stress in rat brain. *Neurotoxicity Research* 13: 63-69.
- Morakinyo AO, Oludare GO, Anifowose AA and Adegoke OA (2012). Protective effects of alpha lipoic acid on carbon tetrachloride-induced liver and kidney damage in rats. *British Journal of Pharmacology and Toxicology* 3: 21-28.
- Pedersen V (1996). Thioxanthene antipsychotics. *European Psychiatry* 11: 236s-236s.
- Pillai A, Parikh V, Terry AV Jr and Mahadik SP (2007). Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. *Journal of Psychiatric Research* 41: 372-386.
- Roberts CK and Sindhu KK (2009). Oxidative stress and metabolic syndrome. *Life Science* 84: 705–712.
- Souza dos Santos P, Saraiva DF, Ferraz da Costa DC, Scofano HM and de Carvalho-Alves PC (2007). Trifluoperazine protects brain plasma membrane Ca(2+)-ATPase from oxidative damaging. *Experimental Brain Research* 177: 347-357.
- Stargardt T, Weinbrenner S, Busse R, Juckel G and Gericke CA (2008). Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. *Journal of Mental Health Policy and Economics* 1: 89-97.
- Thayer WS (1984). Serum lipid peroxides in rats treated chronically with adriamycin. *Biochemical Pharmacology* 33: 2259-2263.
- Tsai G, Goff DC, Chang RW, Flood J, Baer L and Coyle JT (1998). Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. *American Journal of Psychiatry* 155: 1207–1213.
- Tyrer P and Kendall T (2009). The spurious advance of antipsychotic drug therapy. *Lancet* 373: 4-5.

Venkatasubramanian G (2012). The 'Holy Grail' and 'Poisoned Chalice' effects of antipsychotics on oxidative stress in schizophrenia: Can 'Hormesis' explain this paradox? *Indian Journal of Psychological Medicine* 34: 97-98.

Verhagen LA, Luijendijk MC, Hillebrand JJ and Adan RA (2009). Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa. *European Neuropsychopharmacology* 19: 153-160.

World Health Organization (2011). Schizophrenia; [cited February 27, 2011].